- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/28 - Antiandrogens
Patent holdings for IPC class A61P 5/28
Total number of patents in this class: 180
10-year publication summary
8
|
3
|
4
|
3
|
8
|
6
|
11
|
10
|
9
|
6
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Aragon Pharmaceuticals, Inc. | 71 |
9 |
The University of British Columbia | 1518 |
9 |
Taisho Pharmaceutical Co., Ltd. | 863 |
6 |
Suzhou Kintor Pharmaceuticals, Inc. | 59 |
5 |
University of Tennessee Research Foundation | 753 |
5 |
Bayer Schering Pharma AG | 376 |
4 |
British Columbia Cancer Agency Branch | 191 |
4 |
Provincial Health Services Authority | 186 |
4 |
Bayer Pharma AG | 1054 |
3 |
The Johns Hopkins University | 5730 |
3 |
Fundacio Institut de Recerca Biomedica (irb Barcelona) | 72 |
3 |
Institucio Catalana de Recerca I Estudis Avancats | 357 |
3 |
Jiangsu Hengrui Medicine Co., Ltd. | 708 |
3 |
Sloan-Kettering Institute for Cancer Research | 533 |
3 |
ESSA Pharma Inc. | 43 |
3 |
Oncternal Therapeutics, Inc. | 38 |
3 |
Pfizer Inc. | 3396 |
2 |
Koninklijke Philips N.V. | 24957 |
2 |
Sumitomo Chemical Company, Limited | 9092 |
2 |
Takeda Pharmaceutical Company Limited | 2704 |
2 |
Other owners | 102 |